AstraZeneca announced $15 billion investment in China through 2030 to expand manufacturing and R&D, making the company the first global drugmaker with end-to-end cell therapy capabilities in China.
The investment will significantly enhance AstraZeneca’s cell therapy and radioconjugates capabilities, spanning the value chain from drug discovery and clinical development to manufacturing. AstraZeneca will utilize partnerships with leading Chinese biotechs including AbelZeta, CSPC, Harbour BioMed, Jacobio and Syneron Bio.
These commitments build on AstraZeneca’s substantial R&D footprint in China, including global strategic R&D centers in Beijing and Shanghai. The company will also develop its existing manufacturing facilities in Wuxi, Taizhou, Qingdao and Beijing, which provide medicines to patients in China and 70 markets worldwide. AstraZeneca plans to establish new sites, which will be announced in the future.
Together, the investments will grow the company’s skilled workforce in China beyond 20,000 and create thousands of additional jobs.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!